192564-14-0
192564-14-0
Chemical Structure
Oritavancin diphosphate
Synonym(s): LY333328 diphosphate
- CAS No.: 192564-14-0
- Formula:C86H103Cl3N10O34P2
- Molecular Weight:1989.09
InChIKey: PWTROOMOPLCZHB-BHYQHFGMSA-N
SMILES: O[C@@H]1[C@@H](O[C@@](O[C@@H](C)[C@@H]2O)([H])C[C@]2(C)NCC3=CC=C(C4=CC=C(Cl)C=C4)C=C3)[C@@H](O[C@H](CO)[C@H]1O)OC5=C(OC6=CC=C([C@H]([C@H]7NC([C@H](NC)CC(C)C)=O)O)C=C6Cl)C=C([C@](NC([C@@H](NC7=O)CC(N)=O)=O)([H])C(N[C@](C8=O)([H])C9=CC%10=C(O)C=C9)=O)C=C5OC%11=CC=C([C@H]([C@](C(N[C@@](C(O)=O)([H])C%12=C%10C(O)=CC(O)=C%12)=O)([H])N8)O[C@@](O[C@@H](C)[C@@H]%13O)([H])C[C@@]%13(N)C)C=C%11Cl.O=P(O)(O)O.O=P(O)(O)O
Biological Activity: Oritavancin diphosphate (LY333328 diphosphate), a semisynthetic derivative of Vancomycin (HY-B0671), is an orally active glycopeptide antibiotic with bactericidal activity against gram-positive organisms. Oritavancin diphosphate shows antibacterial effect against B. anthracis, such as Ames strain with a MIC value of 0.015 g/mL. Oritavancin diphosphate inhibits cell wall synthesis and disrupts the membrane potential. Oritavancin diphosphate inhibits ArlS kinase activity thereby interfering the signal transduction. Oritavancin diphosphate enters cells by adsorptive endocytosis, which drives it to lysosomes, where it exerts antibiotic activity[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Oritavancin diphosphate | 99.71% | Oritavancin diphosphate (LY333328 diphosphate), a semisynthetic derivative of Vancomycin (HY-B0671), is an orally active glycopeptide antibiotic with bactericidal activity against gram-positive organisms. Oritavancin diphosphate shows antibacterial effect against B. anthracis, such as Ames strain with a MIC value of 0.015 g/mL. Oritavancin diphosphate inhibits cell wall synthesis and disrupts the membrane potential. Oritavancin diphosphate inhibits ArlS kinase activity thereby interfering the signal transduction. Oritavancin diphosphate enters cells by adsorptive endocytosis, which drives it to lysosomes, where it exerts antibiotic activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Oritavancin diphosphate (Standard) | ≥98% | Oritavancin (diphosphate) (Standard) is the analytical standard of Oritavancin (diphosphate). Oritavancin diphosphate (Standard), a semisynthetic derivative of Vancomycin (HY-B0671), is an orally active glycopeptide antibiotic with bactericidal activity against gram-positive organisms. Oritavancin diphosphate (Standard) shows antibacterial effect against B. anthracis, such as Ames strain with a MIC value of 0.015 g/mL. Oritavancin diphosphate (Standard) inhibits cell wall synthesis and disrupts the membrane potential. Oritavancin diphosphate (Standard) inhibits ArlS kinase activity thereby interfering the signal transduction. Oritavancin diphosphate (Standard) enters cells by adsorptive endocytosis, which drives it to lysosomes, where it exerts antibiotic activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Chloroorienticin A | Chloroorienticin A (A82846B) is a glycopeptide antibiotic. Chloroorienticin A exhibits excellent activity against staphylococci and streptococci. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Eremomycin | 95.87% | Eremomycin (MM 45289) is a potent glycopeptide antibiotic closely related to Vancomycin (HY-B0671). Eremomycin shows antibacterial activity in Staphylococcus spp. and Bacillus subtilis ATCC6633, with the MIC values of 0.03-1.6 μg/mL. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Balhimycin | Balhimycin is a glycopeptide antibiotic, found from the fermentation broth of a Amycolatopsis sp. Balhimycin shows anti-bacterial activity against staphylococci and anaerobes. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Vancomycin hydrochloride | 99.47% | Vancomycin hydrochloride is an antibiotic for the treatment of bacterial infections. It acts by inhibiting the second stage of cell wall synthesis of susceptible bacteria. Vancomycin also alters the permeability of the cell membrane and selectively inhibits ribonucleic acid synthesis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N-Nitrosovancomycin | N-Nitrosovancomycin is an antibacterial agent and an N-terminal nitrosated derivative of vancomycin. N-Nitrosovancomycin exhibits antibacterial activity against Gram-positive bacteria in vitro, but shows no activity against Gram-negative E. coli. The modified N-terminal amino group of N-Nitrosovancomycin cannot be protonated, yet the compound still retains in vitro antibacterial activity. N-Nitrosovancomycin can be used in studies related to Gram-positive bacterial infections. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Vancomycin | 99.39% | Vancomycin is an antibiotic for the treatment of bacterial infections. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Oritavancin | Oritavancin (LY 333328), a semisynthetic derivative of Vancomycin (HY-B0671), is an orally active glycopeptide antibiotic with bactericidal activity against gram-positive organisms. Oritavancin shows antibacterial effect against B. anthracis, such as Ames strain with a MIC value of 0.015 g/mL. Oritavancin inhibits cell wall synthesis and disrupts the membrane potential. Oritavancin inhibits ArlS kinase activity thereby interfering the signal transduction. Oritavancin enters cells by adsorptive endocytosis, which drives it to lysosomes, where it exerts antibiotic activity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Norvancomycin monohydrochloride | 95.25% | Norvancomycin hydrochloride is a cell wall synthesis inhibitor targeting peptidoglycan precursors of Gram-positive bacteria and cannot pass the blood-brain barrier. Norvancomycin hydrochloride can competitively bind to peptidoglycan precursors, irreversibly inhibit bacterial cell wall synthesis, and exert antibacterial activity. Norvancomycin hydrochloride is mainly used in the study of Gram-positive bacterial infections, especially infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE). Norvancomycin hydrochloride can also be incorporated into the bionic calcium phosphate coating of titanium implants to enhance antibacterial activity and inhibit postoperative orthopedic infections. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Norvancomycin | N-Demethylvancomycin is a glycopeptide antibiotic which can be extracted from Nocardia orientalis and active against several strains of S. aureus and S. epidermidis. N-Demethylvancomycin can be used for infection research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Helvecardin B | Helvecardin B is a glycopeptidtic antibiotic. Helvecardin B has strong activity of anti-aerobic and anaerobic Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Bai J, et al. The role of ArlRS in regulating oxacillin susceptibility in methicillin-resistant Staphylococcus aureus indicates it is a potential target for antimicrobial resistance breakers[J]. Emerg Microbes Infect. 2019;8(1):503-515. [Content Brief]
- [2]. Van Bambeke F, et al. Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages[J]. Antimicrob Agents Chemother. 2004 Aug;48(8):2853-60. [Content Brief]
- [3]. Heine HS, et al. Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax. Antimicrob Agents Chemother. 2008 Sep;52(9):3350-7. [Content Brief]
- [4]. Arhin FF, et al. Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing. Antimicrob Agents Chemother. 2008 May;52(5):1597-1603. [Content Brief]
- [5]. Coyle EA, et al. Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 2001 Mar;45(3):706-9. [Content Brief]
